When temps rise, so do medical risks. Should doctors and nurses talk more about heat?

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)  Ven­ture cap­i­tal, pri­vate and non-prof­it in­vestors who

Gly­coMimet­ics’ stock $GLYC tanked over 60% in pre­mar­ket trad­ing Mon­day morn­ing af­ter the biotech an­nounced a Phase 3 tri­al fail­ure for its lead drug, up­ro­le­se­lan,